Emyria Limited, a clinical-stage biotech company, engages in the development of treatments for unmet medical needs. The company develops cannabinoid-based medicines, as well as MDMA drug discovery program. Its drug development program includes EMD-RX5 for treatment of psychological distress and irritable bowel syndrome; and EMD-RX7 for multiple medical conditions. The company was formerly known as Emerald Clinics Limited and changed its name to Emyria Limited in September 2020. Emyria Limited was founded in 2018 and is headquartered in Leederville, Australia.

Emyria Limited

Emyria is involved in healthcare services, focusing on the development of innovative therapies and medical products. Self-described as an investment opportunity.

EMD

COM:EMYRIA

Emyria

Last Close

0.04

22/11 05:10

Market Cap

20.86M

Beta: -

Volume Today

229.57K

Avg: -